More Impella left-sided blood pumps are under Class I recall, this time for potential interactions with transcatheter aortic valve replacement (TAVR) stents, the FDA announced Thursday. The affected ...

Johnson & Johnson MedTech today announced new data confirming the benefits of its Abiomed business' Impella CP system.

The artificial intelligence (AI)-based risk tool GRACE 3.0 may better identify patients with non-ST-elevation acute coronary ...

There are new and revised warnings about the instructions for use of a certain type of heart pump that could lead to a risk of heart perforation, according to an alert issued by the pump's ...

For patients who have acute MI with cardiogenic shock (AMICS), Medicare claims data aren’t detailed enough to show whether use of the Impella percutaneous microaxial left ventricular assist device ...

A Japanese registry study reveals how DanGer shock criteria predict survival in heart attack patients treated with Impella.

Use of a microaxial flow pump (Impella CP) with standard care led to a lower risk for death than standard care alone in patients with ST-elevation myocardial infarction (STEMI)-related cardiogenic ...

The FDA has opened up the use of Johnson & Johnson’s miniaturized heart pumps to certain pediatric patients, including those suffering from acute heart failure and cardiogenic shock. The agency ...

DANVERS, Mass., April 8, 2024 – A late breaking clinical trial, presented at the American College of Cardiology conference and simultaneously published in the New England Journal of Medicine, confirms ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start ...

DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed’s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart ...